Nucleus Drugs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 01-02-2024
- Paid Up Capital ₹ 0.10 M
as on 01-02-2024
- Company Age 19 Year, 29 Days
- Last Filing with ROC 31 Mar 2008
About Nucleus Drugs
- CIN/LLPIN
U24230TG2005PTC048507
- Company No.
048507
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Dec 2005
- Date of AGM
26 Sep 2008
- Date of Balance Sheet
31 Mar 2008
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nucleus Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dodda Kumar  | Director | 21-Dec-2005 | Current |
| Gorla Reddy | Director | 21-Dec-2005 | Current |
Financial Performance of Nucleus Drugs.
Enhance accessibility to Nucleus Drugs's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Nucleus Drugs?
Unlock access to Nucleus Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nucleus Drugs?
Unlock and access historical data on people associated with Nucleus Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nucleus Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nucleus Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
